Probi AB
Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally. The company conducts research primarily in the fields of mental, digestive, immune, bone, oral, children's, women's, and senior health, as well as iron absorption. It provides dietary … Read more
Probi AB (PROB) - Net Assets
Latest net assets as of September 2024: Skr1.37 Billion SEK
Based on the latest financial reports, Probi AB (PROB) has net assets worth Skr1.37 Billion SEK as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.52 Billion) and total liabilities (Skr155.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr1.37 Billion |
| % of Total Assets | 89.77% |
| Annual Growth Rate | 11.69% |
| 5-Year Change | 18.83% |
| 10-Year Change | 838.03% |
| Growth Volatility | 77.92 |
Probi AB - Net Assets Trend (2000–2023)
This chart illustrates how Probi AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Probi AB (2000–2023)
The table below shows the annual net assets of Probi AB from 2000 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | Skr1.37 Billion | -2.94% |
| 2022-12-31 | Skr1.41 Billion | +11.46% |
| 2021-12-31 | Skr1.27 Billion | +13.48% |
| 2020-12-31 | Skr1.12 Billion | -3.20% |
| 2019-12-31 | Skr1.15 Billion | +12.03% |
| 2018-12-31 | Skr1.03 Billion | +16.24% |
| 2017-12-31 | Skr884.74 Million | -1.57% |
| 2016-12-31 | Skr898.83 Million | +380.05% |
| 2015-12-31 | Skr187.24 Million | +28.29% |
| 2014-12-31 | Skr145.95 Million | +11.39% |
| 2013-12-31 | Skr131.03 Million | +6.68% |
| 2012-12-31 | Skr122.82 Million | +5.74% |
| 2011-12-31 | Skr116.15 Million | -5.56% |
| 2010-12-31 | Skr122.98 Million | +7.87% |
| 2009-12-31 | Skr114.01 Million | +10.41% |
| 2008-12-31 | Skr103.26 Million | +8.39% |
| 2007-12-31 | Skr95.26 Million | +34.68% |
| 2006-12-31 | Skr70.73 Million | -6.40% |
| 2005-12-31 | Skr75.57 Million | -9.73% |
| 2004-12-31 | Skr83.71 Million | +43.48% |
| 2003-12-31 | Skr58.34 Million | -12.30% |
| 2002-12-31 | Skr66.52 Million | -17.52% |
| 2001-12-31 | Skr80.65 Million | -25.12% |
| 2000-12-31 | Skr107.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Probi AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 40946.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr613.24 Million | 44.79% |
| Common Stock | Skr58.22 Million | 4.25% |
| Other Comprehensive Income | Skr97.42 Million | 7.12% |
| Other Components | Skr600.21 Million | 43.84% |
| Total Equity | Skr1.37 Billion | 100.00% |
Probi AB Competitors by Market Cap
The table below lists competitors of Probi AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wireless Power Amplifier Module Inc
KQ:332570
|
$106.65 Million |
|
Benchmark Bankshares Inc
PINK:BMBN
|
$106.67 Million |
|
Grupo Gicsa S.A. de C.V
MX:GICSAB
|
$106.68 Million |
|
Interflex Co. Ltd
KQ:051370
|
$106.70 Million |
|
Tanvex BioPharma Inc
TW:6541
|
$106.58 Million |
|
Sapura Energy Bhd
KLSE:5218
|
$106.55 Million |
|
B Communications Ltd
PINK:BCOMF
|
$106.54 Million |
|
Polight ASA
OL:PLT
|
$106.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Probi AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,410,567,000 to 1,369,080,000, a change of -41,487,000 (-2.9%).
- Net income of 16,819,000 contributed positively to equity growth.
- Dividend payments of 14,812,000 reduced retained earnings.
- Other comprehensive income decreased equity by 43,493,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr16.82 Million | +1.23% |
| Dividends Paid | Skr14.81 Million | -1.08% |
| Other Comprehensive Income | Skr-43.49 Million | -3.18% |
| Other Changes | Skr-1.00K | -0.0% |
| Total Change | Skr- | -2.94% |
Book Value vs Market Value Analysis
This analysis compares Probi AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 227.96x to 2.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Skr1.53 | Skr348.00 | x |
| 2003-12-31 | Skr1.34 | Skr348.00 | x |
| 2004-12-31 | Skr8.43 | Skr348.00 | x |
| 2005-12-31 | Skr7.61 | Skr348.00 | x |
| 2006-12-31 | Skr7.13 | Skr348.00 | x |
| 2007-12-31 | Skr9.60 | Skr348.00 | x |
| 2008-12-31 | Skr10.40 | Skr348.00 | x |
| 2009-12-31 | Skr11.49 | Skr348.00 | x |
| 2010-12-31 | Skr12.39 | Skr348.00 | x |
| 2011-12-31 | Skr11.90 | Skr348.00 | x |
| 2012-12-31 | Skr12.71 | Skr348.00 | x |
| 2013-12-31 | Skr13.56 | Skr348.00 | x |
| 2014-12-31 | Skr15.11 | Skr348.00 | x |
| 2015-12-31 | Skr19.38 | Skr348.00 | x |
| 2016-12-31 | Skr94.66 | Skr348.00 | x |
| 2017-12-31 | Skr77.65 | Skr348.00 | x |
| 2018-12-31 | Skr90.26 | Skr348.00 | x |
| 2019-12-31 | Skr101.12 | Skr348.00 | x |
| 2020-12-31 | Skr97.88 | Skr348.00 | x |
| 2021-12-31 | Skr111.07 | Skr348.00 | x |
| 2022-12-31 | Skr123.80 | Skr348.00 | x |
| 2023-12-31 | Skr120.16 | Skr348.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Probi AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.68%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 1.09x
- Recent ROE (1.23%) is below the historical average (10.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 21.24% | 26.16% | 0.72x | 1.13x | Skr7.48 Million |
| 2003 | 14.02% | 14.81% | 0.76x | 1.24x | Skr2.35 Million |
| 2004 | 8.80% | 11.58% | 0.68x | 1.11x | Skr-1.00 Million |
| 2005 | 11.69% | 16.09% | 0.66x | 1.10x | Skr1.28 Million |
| 2006 | -6.83% | -12.99% | 0.45x | 1.16x | Skr-11.91 Million |
| 2007 | 25.75% | 56.30% | 0.42x | 1.09x | Skr15.00 Million |
| 2008 | 7.74% | 11.76% | 0.61x | 1.08x | Skr-2.33 Million |
| 2009 | 9.43% | 16.42% | 0.54x | 1.06x | Skr-649.70K |
| 2010 | 11.11% | 17.00% | 0.59x | 1.10x | Skr1.36 Million |
| 2011 | 12.22% | 15.04% | 0.73x | 1.11x | Skr2.58 Million |
| 2012 | 11.00% | 13.45% | 0.73x | 1.11x | Skr1.22 Million |
| 2013 | 11.48% | 14.53% | 0.69x | 1.14x | Skr1.94 Million |
| 2014 | 14.91% | 15.80% | 0.78x | 1.21x | Skr7.17 Million |
| 2015 | 26.19% | 22.71% | 0.95x | 1.22x | Skr30.32 Million |
| 2016 | 12.08% | 24.47% | 0.37x | 1.35x | Skr18.68 Million |
| 2017 | 7.81% | 11.29% | 0.55x | 1.26x | Skr-19.38 Million |
| 2018 | 7.41% | 12.62% | 0.50x | 1.18x | Skr-26.59 Million |
| 2019 | 7.45% | 13.72% | 0.49x | 1.12x | Skr-29.33 Million |
| 2020 | 8.31% | 12.92% | 0.58x | 1.11x | Skr-18.83 Million |
| 2021 | 6.57% | 12.63% | 0.46x | 1.13x | Skr-43.41 Million |
| 2022 | 2.88% | 6.57% | 0.39x | 1.11x | Skr-100.43 Million |
| 2023 | 1.23% | 2.68% | 0.42x | 1.09x | Skr-120.09 Million |
Industry Comparison
This section compares Probi AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $94,923,042
- Average return on equity (ROE) among peers: -56.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Probi AB (PROB) | Skr1.37 Billion | 21.24% | 0.11x | $106.63 Million |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $20.94 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $566.46K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $15.08 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.92 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $559.69K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.88 Million |